IVIG - Mechanisms of action

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 58, Issue 7, 2003, Pages 543-552

  Simon, Hans Uwe ^a   Spath P J ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b ZLB Bioplasma AG   (Switzerland)

Author keywords

Anti inflammatory effect; Antibody titre; Fc receptors; Immunomodulation; IVIG; Mechanism of action

Indexed keywords

ANTIINFLAMMATORY AGENT; CD4 ANTIGEN; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; CYTOKINE ANTIBODY; FAS ANTIGEN; FC RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC URTICARIA; ALLERGY; ANTIBODY TITER; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BLISTER; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR; COMPLEMENT FIXATION; CYTOKINE PRODUCTION; DERMATOMYOSITIS; DOSE RESPONSE; GUILLAIN BARRE SYNDROME; HUMAN; HYPERSENSITIVITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE SYSTEM; IMMUNOMODULATION; MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC EPIDERMAL NECROLYSIS; VASCULITIS;

AGAMMAGLOBULINEMIA; ANTIBODIES; ANTIBODIES, ANTI-IDIOTYPIC; AUTOIMMUNITY; COMMON VARIABLE IMMUNODEFICIENCY; HUMANS; IMMUNE SYSTEM; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS;

EID: 0038300763     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2003.00239.x     Document Type: Review

References (98)

1. KAZATCHKINE MD, KAVERI SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-755.
2. EMMI L, CHIARINI F. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci 2002;23(Suppl. 1):S1-S8.
3. LARROCHE C, CHANSEAUD Y, Garcia de la PENA-LEFEBVRE, MOUTHON L. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. BioDrugs 2002;16:47-55.
4. SEWELL WA, JOLLES S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002;107:387-393.
5. POLLACK M. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis 1983;147:1090-1098.
6. FISCHER GW, HUNTER KW, HEMMING VG, WILSON SR. Functional antibacterial activity of a human intravenous immunoglobulin preparation: In vitro and in vivo studies. Vox Sang 1983;44:296-299.
7. FISCHER GW, HEMMING VG, GLOSER HP et al. Polyvalent group-B streptococcal immune globulin for intravenous administration - overview. Rev Infect Dis 1990;12:S483-S491.
8. GIVNER LB, BAKER CJ. Pooled human IgG hyperimmune for type-III group-B Streptococci - Evaluation against multiple strains invitro and in experimental disease. J Infect Dis 1991;163:1141-1145.
9. CUNNINGHAM-RUNDLES C, HANSON LA, HITZIG WH et al. Appropriate uses of human immunoglobulin in clinical practice: Memorandum from an UIS/WHO meeting. Bull WHO 1982;60:43-47.
10. NORRBY-TEGLUND A, BASMA H, ANDERSSON J, MCGEER A, LOW DE, KOTB M. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: Implications for therapeutic efficacy. Clin Infect Dis 1998;26:631-638.
11. LAMARI F, ANASTASSIOU ED, TSEGENIDIS T, DIMITRACOPOULOS G, KARAMANOS NK. An enzyme immunoassay to determine the levels of specific anti-bodies toward bacterial surface antigens in human immunoglobulin preparations and blood serum. J Pharm Biomed Anal 1999;20:913-920.
12. MATEJTSCHUK P, CHIDWICK K, PRINCE A, MORE JE, GOLDBLATT D. A direct comparison of the antigen-specific antibody profiles of intravenous immunoglobulins derived from US and UK donor plasma. Vox Sanguinis 2002;83:17-22.
13. TERNESS P, OPELZ G. Natural anti-immunoglobulin autoantibodies: Irrelevant by-products or immunoregulatory molecules? Int Arch Allergy Immunol 1998;115:270-277.
14. CUKROWSKA B, SINKORA J, HANDEL L et al. Thymic B cells of pig fetuses and germ-free pigs spontaneously produce IgM, IgG and IgA: detection by ELISPOT method. Immunology 1996;87:487-492.
15. CUKROWSKA B, SINKORA J, REHÁKOVÁ Z et al. Isotype and antibody specificity of spontaneously formed immunoglobulins in pig fetuses and germ-free piglets: Production by CD5 B cells. Immunology 1996;88:611-617.
16. BACCALA R, VO QUANG T, GILBERT M, TERNYNCK T, AVRAMEAS S. Two murine natural polyreactive autoantibodies are encoded by nonmutated germ-line genes. PNAS 1989;86:4624-4628.
17. BERNEMAN A, GUILBERT B, ESCHRICH S, AVRAMEAS S. IgG auto and polyreactivities of normal human sera. Mol Immunol 1993;30:1499-1510.
18. PRABHAKAR BS, SAEGUSA J, ONODERA T, NOTKINS AL. Lymphocytes capable of making autoantibodies that react with multiple organs are a sommon feature of the normal B cell repertoire. J Immunol 1984;133:2815-2820.
19. OCHSENBEIN AF, FEHR T, LUTZ C et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999;286:2156-2159.
20. GUINAMARD R, OKIGAKI M, SCHLESSINGER J, RAVETCH JV. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat Immunol 2000;1:31-36.
21. FAGARASAN S, HONJO T. T-independent immune response: new aspects of B cell biology. Science 2000;290:89-91.
22. LUTZ HU. How pre-existing, germline-derived antibodies and complement may help induce a primary immune response to nonself. Scand J Immunol 1999;49:224-228.
23. THORNTON BP, VETVICKA V, ROSS GD. Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J Immunol 1994;152:1727-1737.
24. OHTEKI T, HESSEL A, BACHMANN MF et al. Identification of a cross-reactive self ligand in virus-mediated autoimmunity. J Immunol 1999;29:2886-2896.
25. LEUNG DYM, MEISSNER HC, FULTON DR, MURRAY DL, KOTZIN BL, SCHLIEVERT PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993;342:1385-1388.
26. HORWITZ MS, SARVETNICK N. Viruses, host responses, and autoimmunity. Immunol Rev 1999;169:241-253.
27. ROSSI F, KAZATCHKINE MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989;143:4104-4109.
28. SULTAN Y, KAZATCHKINE MD, MAISONNEUVE P, NYDEGGER UE. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high dose intravenous gammaglobulin. Lancet 1984;II:765-768.
29. LUNDKVIST I, VAN DOORN PA, VERME-ULEN M, BRAND A. Spontaneous recovery from the Guillain-Barre syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies. Clin Immunol Immunopathol 1993;67:192-198.
30. BUCHWALD B, AHANGARI R, WEISHAUPT A, TOYKA KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann Neurol 2002;51:673-680.
31. VAN DOORN PA, ROSSI F, BRAND A, VAN LINT M, VERMEULEN M, KAZATCHKINE MD. On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1990;29:57-64.
32. DWYER DS, BRADLEY RJ, URQUART CK, KEARNEY JF. Naturally occurring anti-idiotypic antibodies in myasthenia gravis patients. Nature 1983;301:611-614.
33. ROSSI F, JAYNE DRW, LOCKWOOD CM, KAZATCHKINE MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991;83:298-303.
34. DIETRICH G, KAZATCHKINE MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contains anti-idiotypic specificies against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990;85:620-625.
35. BERCHTOLD P, DALE GL, TANI P, MCMILLAN R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989;74:2414-2417.
36. MARCHALONIS JJ, KAYMAZ H, DEDEOGLU F, SCHLUTER SF, YOCUM DE, EDMUNDSON AB. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta-chain. PNAS 1992;89:3325-3329.
37. KLAESSON S, RINGDEN O, MARKLING L, REMBERGER M, LUNDKVIST I. Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. Scand J Immunol 1993;38:477-484.
38. COGGESHALL KM. Inhibitory signaling by B cell FcγRIIb. Curr Opin Immunol 1998;10:306-312.
39. HUREZ V, KAVERI SV, MOUHOUB A et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol 1994;1:269-277.
40. KAVERI S, VASSILEV T, HUREZ V et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996;97:865-869.
41. PHAN TG, WONG RC, CROTTY K, ADELSTEIN S. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Aus J Dermatol 1999;40:153-157.
42. ANDRESEN M, BOGHERO Y, MOLGO M, DOUGNAO A, DIAZ O. Toxic epidermal necrolysis. Therapy in ICU with intravenous immunoglobulins in a case. Rev Med Chil 2000;128:1343-1348.
43. MAGINA S, LISBOA C, GONCALVES E, CONCEICAO F, LEAL V, MESQUITA-GUIMARAES J. A case of toxic epidermal necrolysis treated with intravenous immunoglobin. Br J Dermatol 2000;142:191-192.
44. PAQUET P, JACOB E, DAMAS P, PIERARD GE. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns 2001;27:652-655.
45. VIARD I, WEHRLI P, BULLANI R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-493.
46. PRINS C, KERDEL FA, PADILLA RS et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26-32.
47. TRAUTMANN A, AKDIS M, SCHMID-GRENDELMEIER P et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 2001;108:839-846.
48. PRASAD NKA, PAPOFF G, ZEUNER A et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998;161:3781-3790.
49. VARAMBALLY S, PRASAD N, BONNIN E et al. Phosphorylation of Bcl-2 and mitochondrial changes are associated with apoptosis of lymphoblastoid cells induced by normal immunoglobulin G. Biochem Biophys Res Commun 1999;264:896-901.
50. SIMON HU, YOUSEFI S, DOMMANN-SCHERRER CC et al. Expansion of cytokine-producing CD4-CDS- T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med 1996;183:1071-1082.
51. DAIGLE I, YOUSEFI S, COLONNA M, GREEN DR, SIMON HU. Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat Med 2002;8:61-67.
52. HEBESTREIT H, YOUSEFI S, BALATTI I et al. Expression and function of the fas receptor on human blood and tissue eosinophils. Eur J Immunol 1996;26:1775-1780.
53. BENDTZEN K, SVENSON M, HANSEN M. Autoantibodies to cytokines in IVIG. J Rheumatol 1993;20:2176-2177.
54. ABE Y, HORIUCHI A, MIYAKE M, KIMURA S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5-19.
55. ROSS C, SVENSON M, HANSEN MB, VEIJLSGAARD GL, BENDTZEN K. Specific autoantibodies directed against interferon-α in pharmaceutically prepared human immunoglobulin preparations. J Interferon Res 1994;14:159-160.
56. EMMENEGGER U, FREY U, REIMERS A et al. Hyperferritinemia as indicator for intravenous immunogloblin treatment in reactive macrophage activation syndromes. Am J Hematol 2001;68:4-10.
57. FARBER CM, CRUSIAUX A, SCHANDENE L et al. Tumor necrosis factor and intravenous gammaglobulins in common variable immunodeficiency. Clin Immunol Immunopathol 1994;72:233-236.
58. AUKRUST P, FROLAND SS, LIABAKK NB et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84:2136-2143.
59. WOLF HH, DAVIES SV, BORTE M et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003;84:45-53.
60. ROUX KH, TANKERSLEY DL. A view of the human idiotypic repertoire - electron microscopic and immunologic analyses of spontaneous idiotype-antiidiotype dimers in pooled human IgG. J Immunol 1990;144:1387-1395.
61. TANKERSLEY DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 1994;139:159-172.
62. TEELING JL, JANSEN-HENDRIKS T, KUIJPERS TW et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G directs: studies in experimental immune thrombocytopenia. Blood 2001;98:1095-1099.
63. TEELING JL, BLEEKER WK, RIGTER GM, VAN ROOIJEN N, KUIJPERS TW, HACK CE. Intravenous immunoglobulin preparations induce mild activation of neutrophils in vivo via triggering of macrophages - studies in a rat model. Br J Haematol 2001;112:1031-1040.
64. PRICOP L, REDECHA P, TEILLAUD JL et al. Differential modulation of stimulatory and inhibitory Fcgamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol 2001;166:531-537.
65. SHARIEF MK, INGRAM DA, SWASH M, THOMPSON EJ. I.v. immunoglobulin reduces circulating proinflammatory cytokmes in Guillain-Barré syndrome. Neurology 1999;52:1833-1838.
66. SAMUELSSON A, TOWERS TL, RAVETCH JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-486.
67. DAVIS RS, WANG YH, KUBAGAWA H, COOPER MD. Identification of a family of Fc receptor homologs with preferential B cell expression. PNAS 2001;98:9772-9777.
68. HATZIVASSILIOU G, MILLER I, TAKIZAWA J et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 2001;14:277-289.
69. YU Z, LENNON VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340:227-228.
70. HANSEN RJ, BALTHASAR JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 2002;88:898-899.
71. BASTA M, KIRSHBOM P, FRANK MM, FRIES LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989;84:1974-1981.
72. n -IgG complexes. Blood 1996;88:184-193.
73. BASTA M, DALAKAS MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-1735.
74. LUTZ HU, STAMMLER P, SPÄTH PJ, HESS-SCHMID M, TRÜEB RM, JELEZAROVA E. High dose pooled human IgG (IVIG) has a complement attenuating effect in vivo in an inflammatory disease. Mol Immunol 1998;35:368A.
75. NEWBURGER JW, TAKAHASHI M, BEISER AS et al. A single intravenous infusion of gamma-globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-1639.
76. NEWBURGER JW, TAKAHASHI M, BURNS JC et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-347.
77. HUGHES RAC, SWAN AV, CORNBLATH DR, HARTUNG HP. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatment in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997;349:225-230.
78. BLANCHETTE V, IMBACH P, ANDREW M et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994;344:703-707.
79. HUGHES RA, BENSA S, WILLISON H et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
80. LÉGER JM, CHASSANDE B, MUSSET L, MEININGER V, BOUCHE P, BAUMANN N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001;124:145-153.
81. DALAKAS MC, ILLA I, DAMBROSIA JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
82. ARSURA EL, BICK A, BRUNNER NG, NAMBA T, GROB D. High-dose intravenous immunoglobulin in the management of Myasthenia gravis. Arch Intern Med 1986;146:1365-1368.
83. JAYNE DR, CHAPEL H, ADU D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000;93:433-439.
84. FRANCIONI C, FIORAVANTI A, GELLI R, MEGALE F, MARCOLONGO R. Longterm treatment with i.v. immunoglobulin in the therapy of systemic lupus erythematosus. Recent Prog Med 1993;84:679-686.
85. LEVY Y, SHERER Y, AHMED A et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus 1999;8:705-712.
86. PAPO T. Polyvalent intravenous immunoglobulins in systemic lupus. Rev Med Intern 1999;20(Suppl. 4):414S-418S.
87. JOLLES S. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol 2001;26:127-131.
88. O'DONNELL BF, BARR RM, KOBZA-BLACK A et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998;138:101-106.
89. TRENT JT, KIRSNER RS, ROMANELLI P, KERDEL FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 2003;139:39-43.
90. HARMAN KE, WHITTAM LR, WAKELIN SH, BLACK MM. Severe, refractory epidermolysis bullosa acquisita complicated by an oesophageal stricture responding to intravenous immune globulin. Br J Dermatol 1998;139:1126-1127.
91. STELLA M, CASSANO P, BOLLERO D, CLEMENTE A, GIORIO G. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001;203:45-49.
92. TRISTANI-FIROUZI P, PETERSEN MJ, SAFFLE JR, MORRIS SE, ZONE JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002;47:548-552.
93. OEHLING AG, AKDIS CA, SCHAPOWAL A, BLASER K, SCHMITZ M, SIMON HU. Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma. Allergy 1997;52:144-154.
94. SIGMAN K, GHIBU F, SOMMERVILLE W et al. Intravenous immunoglobulin inhibits IgE production in human B lymphocytes. J Allergy Clin Immunol 1998;102:421-427.
95. LANDWEHR LP, JEPPSON JD, KATLAN MG et al. Benefits of high-dose i.v. immunoglobulin in patients with severe steroid-dependent asthma. Chest 1998;114:1349-1356.
96. RABINOVITCH N, GELFAND EW, LEUNG DY. The role of immunoglobulin therapy in allergic diseases. Allergy 1999;54:662-668.
97. HAMILOS DL, CHRISTENSEN J. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. J Allergy Clin Immunol 1991;88:823-824.
98. GELFAND EW, LANDWEHR LP, ESTERL B, MAZER B. Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol 1996;104:61-66.